GlassScriptPhysician profile
Charles Jacob Schechter
NPI 1487654125
$2,306.25
in general payments reported to CMS, 2019-2025
22 companies · $56.54 in 2025
The $56.54 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $232 · 2021: $445 · 2022: $335 · 2023: $397 · 2024: $144 · 2025: $56.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $488.62 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $204.44 | 2019-2020 | |
| Pfizer INC. | $143.09 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $139.42 | 2019-2023 | |
| Esperion Therapeutics, INC. | $132.74 | 2020-2021 | |
| Abbott Laboratories | $122.61 | 2021-2024 | Mitraclip |
| Merck Sharp & Dohme LLC | $121.79 | 2021-2023 | Verquvo |
| Medtronic, INC. | $119.47 | 2021-2022 | |
| Teleflex LLC | $115.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $105.48 | 2019-2023 | Eliquis, Camzyos |
| Abiomed | $102.80 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.34 | 2021-2023 | Jardiance |
| Amgen INC. | $76.32 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.83 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $68.84 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $51.98 | 2019-2021 | |
| Boston Scientific Corporation | $42.05 | 2022-2024 | |
| Cvrx, INC. | $35.95 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $25.97 | 2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $17.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.22 | 2019 | |
| Lilly USA, LLC | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.